Navigation Links
A Basic Symptom Index For Early Detection Of Ovarian Cancer

An index comprising of the basic symptoms associated with ovarian cancer may aid clinicians detect ovarian cancer in its early stages, according to a new study.// This index is expected to serve as a rapid, cost-effective screening tool.

The details of this study is published in the January 15, 2007 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study reveals that early ovarian cancer may be distinguished from other causes by a specific set of symptoms and their frequency and duration.

Physicians generally consider ovarian cancer to be a "silent killer." That is, it develops asymptomatically or with symptoms easily attributable to benign causes until diagnosed late in the course of disease and well after a cure is likely. There is no effective screening test to detect early stage disease in the general population or even high-risk groups. Consequently, no professional gynecology association or public health agency recommends routine screening. The lack of a recognized index of early clinical signs and symptoms,delays diagnosis until disease has advanced. These factors combine to make ovarian cancer one of the deadliest malignancies in the world.

Recent evidence suggests that early-stage symptoms may be recognizable and could be used to develop a symptom index for early disease. Led by Barbara A. Goff, M.D. of the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center in Seattle, researchers compared the clinical history of women at high risk for developing ovarian cancer and women already diagnosed with ovarian cancer to develop a basic symptom index to screen for ovarian cancer.

They found "that a relatively simple evaluation of symptoms of recent onset and significant frequency" was sufficient to be a potential screening tool. Any complaint of pelvic/abdominal pain, increased abdominal size/bloating, or difficulty eating/feeling full that is present more than 12 days per month and for less than one year was 57 percent sensitive for early disease and 80 percent sensitive for advanced cancer; and 90 percent specific for women over 50 years of age and 86.7 percent for women under 50 years of age.

While Dr. Goff plans on evaluating a simple three question screening in a multi-year study in general clinical practice, "a symptom index, though, is only one of a number of promising research tracks the ovarian cancer advocacy community actively supports," writes Sherry Salway Black, Executive Director of the Ovarian Cancer National Alliance in Washington, D.C. in an accompanying editorial from the same issue. Although years away, the development of a screening blood test would be "the real key to early detection." She continues, "until there is a valid screening test, the symptom index could serve an important role in detecting cancers, and after a test is identified, the index could be a tool used in combination with other methods to contribute to early detection." In the meantime, according to Ms. Salway Black, health organizations will continue to educate women and physicians about "the symptoms so that if cancer develops, it is diagnosed early" because "at present, awareness of these symptoms is our best hope for early detection."



Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Getting Basic Science to Work For Medicine
2. Understanding Basic Motor Skills
3. Basic Medical Services Back On Rail In Delhi
4. Basic Instinct drives wannabe moms
5. Lack of Basics Health Awareness Results in Escalating Hospital Expenditure
6. Easing Kids into the Basics of Back to School
7. Naked truths and Basic Instincts
8. A hormone may decrease Menopause Symptoms
9. Heart Attack Symptoms in Women
10. Heart Attack Symptoms Different in Women
11. Symptoms Found To Be A Good Predictor Of Cancer Survival
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: